• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-08-18

  The reference paper highlights how daily oral mavorixafor translates CXCR4 biology into a targeted treatment strategy for WHIM syndrome. In a placebo-controlled phase 3 study, the CXCR4 antagonist prolonged periods of adequate neutrophil and lymphocyte counts and reduced infections, while leaving important questions about long-term outcomes unresolved.

• Removing Pollen Interference in EEM Bioaerosol Detection

  2026-08-17

  Zhang and colleagues developed a fluorescence-spectral preprocessing and random forest workflow to reduce pollen interference during hazardous bioaerosol classification. Fast Fourier transform treatment improved classification accuracy to 89.24%, supporting more reliable discrimination of bacterial and toxin-related signals in complex airborne samples.

• Enhanced ECL Detection Kit: Western Blot Guide

  2026-08-17

  The Enhanced ECL detection kit supports sensitive HRP-based western blot chemiluminescence detection when weak protein bands or limited sample are important. It is intended for HRP-linked protein immunodetection and should not be treated as a universal substrate for non-HRP labels or as independent evidence of quantitative performance.

• Metformin Attenuates Vocal Fold Fibrosis via AMPK

  2026-08-16

  A 2025 study reports that metformin reduced collagen deposition and profibrotic marker expression in rabbit vocal fold injury and TGF-β1-stimulated fibroblast models. Its key contribution is linking these effects to AMPK activation and suppression of the TGF-β/Smad axis, providing a mechanistic basis for further preclinical investigation rather than clinical treatment conclusions.

• TAI-1 and RB1 Loss: Better Cancer Assays

  2026-08-15

  TAI-1 is a potent Hec1 inhibitor whose mitotic mechanism can be studied more intelligently in genetically and developmentally defined cancer models. This article connects Hec1-Nek2 biology with RB1-deficient retinal organoid findings to improve assay design without overstating retinoblastoma efficacy.

• Saikosaponin D Reverses TNBC Radioresistance

  2026-08-14

  The reference study identifies lactate-driven MRE11 Lys673 lactylation as a mechanism of radiotherapy resistance in triple-negative breast cancer and places HDAC5 within a HIF1α-regulated corrective pathway. Its findings connect tumor glycolysis, DNA double-strand break repair, and radiosensitization, offering a mechanistic framework for cancer metabolism research and experimental therapy design.

• Betulinic Acid, ERK, and Cyclophosphamide Liver Injury

  2026-08-14

  This reference study identifies a mechanistic basis for betulinic acid protection against cyclophosphamide-induced liver injury by connecting NRF2 antioxidant responses with ERK-regulated mitochondrial apoptosis. Its use of PD98059 as a pathway-interrogation tool strengthens the evidence that ERK signaling contributes to oxidative damage, mitochondrial remodeling, and hepatocyte apoptosis.

• GSK621: AMPK Agonism for Translational AML Research

  2026-08-13

  GSK621 offers translational researchers a precise way to interrogate AMPK-driven metabolic stress, AML vulnerability, autophagy, apoptosis, and tumor immunometabolism. This article connects AML-focused validation with emerging evidence that lysosomal cholesterol signaling reprograms tumor-associated macrophages through AMPK.

• AI-10-49: Mapping the CBFβ-SMMHC Survival Circuit

  2026-08-13

  AI-10-49 is a selective CBFβ-SMMHC inhibitor that enables researchers to connect RUNX1 reactivation with MYCN-dependent leukemia survival. This article presents an assay-centered framework for acute myeloid leukemia research, integrating protein dissociation, chromatin occupancy, transcriptional response, and in vivo validation.

• Entinostat (MS-275) HDAC Research Workflows

  2026-08-12

  Entinostat (MS-275) combines class I HDAC1/3 selectivity with practical utility across cancer, retinoblastoma, and axolotl regeneration models. This workflow-focused guide covers assay design, formulation, quantitative readouts, and troubleshooting so researchers can separate epigenetic target engagement from nonspecific toxicity.

• Metformin HCl in Vocal Fold Fibrosis Research

  2026-08-12

  Explore how Metformin Hydrochloride (Metformin HCl) can be used to interrogate AMPK-dependent antifibrotic mechanisms in vocal fold injury models. This guide translates rabbit and fibroblast evidence into assay design, formulation, controls, and interpretation decisions.

• Caspase-4 Colorimetric Assay Kit Workflow

  2026-08-11

  Turn LEVD-dependent caspase-4 activity into a practical readout for pyroptosis, inflammasome signaling, and treatment-response studies. This workflow pairs the Caspase-4 Colorimetric Assay Kit with organelle-targeted cancer research while clearly separating caspase-4 activation from general cell death.

• EZ Cap™ Human PTEN mRNA: Translational Strategy

  2026-08-11

  A mechanistic and strategic guide to using EZ Cap™ Human PTEN mRNA (ψUTP) as an in vitro transcribed mRNA tool for restoring PTEN biology, interrogating PI3K/Akt signaling, and designing translational cancer research programs around therapeutic resistance.

• PTEN mRNA Nanoparticles Reverse Trastuzumab Resistance

  2026-08-10

  Dong and colleagues developed tumor-microenvironment-responsive nanoparticles for systemic PTEN mRNA delivery in trastuzumab-resistant HER2-positive breast cancer. The study links conditional nanoparticle uptake and restored PTEN expression to PI3K/Akt signaling pathway inhibition, providing a mechanistically focused strategy for re-sensitizing tumors to trastuzumab.

• ω-Agatoxin IVA TFA: Assay Design Guide

  2026-08-09

  Learn how ω-Agatoxin IVA TFA (SKU C8722) can improve mechanistic interpretation in neuronal calcium, synaptic transmission, and viability workflows. This scenario-based guide explains concentration selection, Cav2.1 subtype interpretation, storage, and vendor-selection criteria using current structural evidence.

8482 records 7/566 page Previous Next First page 上5页 678910 下5页 Last page